Age at Orchiopexy and Testis Palpability Predict Germ and Leydig Cell Loss: Clinical Predictors of Adverse Histological Features of Cryptorchidism
Purpose
We determined the relationship between clinical variables and testicular histopathological changes associated with decreased fertility potential in children with cryptorchidism.
Materials and Methods
Testis biopsies of 274 children who underwent orchiopexy and concurrent testicular biopsy between 1991 and 2001 were analyzed for germ and Leydig cell loss, and testicular fibrosis. Multivariable logistic regression was used to determine if age at orchiopexy (analyzed as continuous and ordinal variables), preoperative testis palpability, unilateral vs bilateral disease and/or side of undescended testis was predictive of these pathological outcomes.
Results
Age at orchiopexy was associated with germ and Leydig cell depletion. Each month of testis undescent was associated with development of moderate/severe germ cell depletion (OR 1.02 for each month of age, p <0.005) and Leydig cell loss (OR 1.01 for each month of age, p <0.02). Nonpalpable testes were associated with severe germ cell depletion. Children with palpable testes had lower odds of germ cell depletion than those with nonpalpable testes (OR 0.46, p <0.005). This finding corresponds to a significant 2% risk per month of severe germ cell loss and 1% risk per month of Leydig cell depletion for each month a testis remains undescended, and a 50% greater risk of germ cell depletion in nonpalpable relative to palpable cryptorchid testes.
Conclusions
Testes that remain undescended are associated with progressive loss of germ and Leydig cells, and nonpalpable testes predict severe germ cell loss.
Key Words: cryptorchidism, fertility, testis, urogenital surgical procedures
Abbreviations and Acronyms: UCSF, University of California–San Francisco
To access this article, please choose from the options below
Funded by Department of Urology, University of California–San Francisco.
Study received institutional committee on human research approval.
See Editorial on page 427.
PII: S0022-5347(09)00941-0
doi:10.1016/j.juro.2009.04.032
© 2009 American Urological Association. Published by Elsevier Inc. All rights reserved.
Refers to article:
- Prostate Specific Antigen, Pelvic Pain and Prostatitis—Time For a New Paradigm? , 15 June 2009

